DexCom, Inc. $DXCM Holdings Trimmed by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 748,438 shares of the medical device company’s stock after selling 225,362 shares during the period. Russell Investments Group Ltd.’s holdings in DexCom were worth $64,583,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Latitude Advisors LLC acquired a new stake in shares of DexCom in the third quarter worth $32,000. Hilton Head Capital Partners LLC grew its holdings in shares of DexCom by 242.3% during the third quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock valued at $33,000 after buying an additional 269 shares in the last quarter. Elevation Wealth Partners LLC grew its holdings in shares of DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after buying an additional 152 shares in the last quarter. GK Wealth Management LLC purchased a new position in shares of DexCom during the third quarter valued at $35,000. Finally, Signature Equity Partners LLC raised its position in DexCom by 97.3% during the third quarter. Signature Equity Partners LLC now owns 436 shares of the medical device company’s stock valued at $38,000 after buying an additional 215 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 2.4%

DXCM traded up $1.94 during trading on Friday, reaching $83.33. 3,013,451 shares of the stock traded hands, compared to its average volume of 5,026,628. The stock has a market cap of $31.08 billion, a price-to-earnings ratio of 32.68, a price-to-earnings-growth ratio of 1.34 and a beta of 1.45. DexCom, Inc. has a fifty-two week low of $56.72 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.74 and a quick ratio of 1.40. The stock’s 50-day simple moving average is $84.30 and its two-hundred day simple moving average is $75.21.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The firm had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the company posted $0.61 earnings per share. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. As a group, equities research analysts expect that DexCom, Inc. will post 2.68 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on DXCM. Wells Fargo & Company increased their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Argus lifted their target price on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Stifel Nicolaus set a $95.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a report on Sunday, September 6th. Finally, BTIG Research increased their price target on shares of DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has an average rating of “Buy” and an average price target of $95.50.

Insider Transactions at DexCom

In related news, EVP Jereme Sylvain sold 3,638 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president owned 98,185 shares in the company, valued at $8,392,853.80. This represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,822 shares of company stock valued at $1,920,193 in the last quarter. Corporate insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.